Right now, doctors at select centers in the U.S. are accepting participants for a new clinical research study.
This study is for a new investigational oral drug for migraines that aims to reduce the pain from migraines. In past studies, more than 3 times the number of patients who responded to treatment preferred rimegepant over their previous therapy.
Clinicians use a number of pharmacologic agents for the acute treatment of migraine, but there remains a significant unmet medical need for a novel migraine-specific medication that does not increase the risk of cardiovascular liability.
Coastal Carolina Research Center is looking for qualified volunteers who:
Rimegepant is an oral medication.
In each trial, a single dose of rimegepant, without any rescue medications, was superior to placebo for pain freedom and pain relief. The efficacy and safety profile of rimegepant has now been observed across three randomized controlled trials, including a Phase 2b study.
Fill out the form, call us at 843-856-3784 and Press # 1, or email Samantha at email@example.com